News Release

Insilico Medicine Leadership to speak at 3 major forums on AI commercialization and clinical validation

Meeting Announcement

InSilico Medicine

November 25 | Abu Dhabi Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to speak at the 2026 Momentum and Growth Conference hosted by Arabian Business in Abu Dhabi.

image: 

On November 25 at 11:30 AM, he will join the panel discussion titled "How the UAE is shaping the future of business with AI" to share his insights.

view more 

Credit: Insilico Medicine

November 25 | Abu Dhabi

Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to speak at the 2026 Momentum and Growth Conference hosted by Arabian Business in Abu Dhabi. On November 25 at 11:30 AM, he will join the panel discussion titled "How the UAE is shaping the future of business with AI" to share his insights.

The panel will examine how AI translates from national strategy into tangible enterprise output. In recent years, the UAE has positioned artificial intelligence as a central pillar of its economic diversification, advancing systematically across computing infrastructure, sovereign AI funds, and industry-specific pilots. For individual sectors, however, the critical question remains whether AI models can be converted into deliverable products. Insilico Medicine’s approach offers a practical blueprint: by integrating its Pharma.AI platform with an automated biology laboratory, the company structures "computation–design–experimentation–feedback" into an R&D workflow capable of continuously nominating candidate compounds and advancing them into clinical trials.

About The Briefing with Arabian Business

The Briefing with Arabian Business is the flagship business summit of Arabian Business. Its inaugural edition was held in Dubai in June 2026, bringing together over 500 attendees and more than 30 speakers. Taking place on November 25 at Rosewood Abu Dhabi under the theme Momentum and Growth, the second edition covers investment, infrastructure and connectivity, tourism and culture, technology and AI, finance, real estate, and global talent competition—highlighting Abu Dhabi’s role as an international hub for business and investment.

November 26 | Hong Kong

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend the 2026 Capital Market Hong Kong Forum in Hong Kong and will deliver a keynote speech from 13:20 to 14:30 on November 26. Dr. Zhavoronkov will delve into how artificial intelligence is transitioning from cutting-edge technological breakthroughs to large-scale commercial applications, and analyze the profound impact and new opportunities this trend brings to global investors and the asset management industry.

About the 2026 Capital Market Hong Kong Forum

Hosted by China Fund News, the forum will be held on November 26, 2026, at CITIC Tower in Admiralty, Hong Kong. Under the theme "Breaking Boundaries and Innovating Forward, AI-Empowered Practice: Global Asset Management in Action and Innovation," the forum aims to bring together HKSAR government agencies, leading domestic and international asset management institutions, and top global AI technology companies to explore asset management industry transformation and new long-term capital allocation opportunities as AI moves from a technological wave toward widespread adoption.

November 26–28 | Shanghai

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 6th Annual Meeting of the Chinese Society for Cell and Gene Therapy in Shanghai. On November 26 at 15:00, he will speak at Track 1: Omics and AI Frontiers for Cell and Gene Therapy, delivering a keynote presentation titled "From Technological Breakthrough to Clinical Validation: The Second Half of AI-Driven Drug Discovery". Research and development in cell and gene therapy are increasingly leveraging multi-omics data and artificial intelligence approaches for target discovery, molecular design, and translational research. As the integration of AI and life sciences continues to deepen, advancing technological innovation toward clinical validation and generating translatable R&D outcomes has become a critical focus across the industry.

About the 6th Annual Meeting of the Chinese Society for Cell and Gene Therapy

Organized by the Cell and Gene Therapy Branch of the Chinese Society for Cell Biology, the 6th Annual Meeting will take place from November 26 to 28, 2026, at the Zhangjiang Science Hall in Shanghai. The conference aims to foster exchange and collaboration in the field of cell and gene therapy, showcase the latest scientific achievements, clinical practices, and frontier technological innovations, and discuss industry hotspots and future development directions. Featuring keynote presentations in the main plenary session alongside multiple thematic tracks, the event will also include a Young Elite Forum, project roadshows, and poster sessions, building a multi-tiered platform for exchange among academia, clinical practitioners, and industry leaders.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.